


The epidemiology of haemangiosarcoma in dogs under veterinary care in the UK in 2019



BACKGROUND

Haemangiosarcoma (HSA) is a malignant neoplasia that originates from vascular endothelial cells. Visceral forms of HSA have an extremely poor prognosis and few dogs live 1 year beyond diagnosis¹.

AIMS and OBJECTIVES

- Estimate the frequency of canine HSA in dogs ≥ 5 years old in the UK in 2019.
- Evaluate signalment and socioeconomic risk factors of HSA in dogs ≥ 5 years old in the UK in 2019.

RESULTS

Incident cases: 790 dogs, Controls: 1,065,382 dogs
Incidence: 0.035% (95% CI: 0.03-0.38)

39.5% of cases were confirmed with **histopathology**.

Of cases that were known to have died, **87.7%** died of causes **related to HSA**.

METHOD



Clinical records from over 1,800 veterinary practices in the UK. Dogs with at least one clinical record in 2019. **Denominator population = 2,250,741 dogs**

2019
 haemangios*, hemangios*, HSA (not case-sensitive), angiosa*, haemangiosarcoma~1, hemangiosarcoma~1, hameangios*


Candidate cases manually assessed and classified into cases and non-cases:

- *Incidence cases: diagnosed by a vet or histopathology between 1st Jan and 31st Dec 2019 (inclusive).*


Non-candidate cases used as control population.
 Age of controls and cases restricted to ≥ 5 years old.

Statistical analysis

- Prevalence and incidence calculations
- Univariable analysis – Fisher's exact test, X² test, Mann-Whitney U test.
- Fixed effect multivariable logistic regression modelling ($p < 0.05$).



Multivariable analysis of signalment risk factors for HSA in dogs ≥ 5 years old in the UK in 2019



CONCLUSIONS

- Canine HSA had an incidence of 0.035% in dogs ≥ 5 years old in the UK in 2019.
- Breed and age had the strongest multivariable associations, however, sex/neuter status, practice group and clinic deprivation also contribute to canine haemangiosarcoma in the UK.

ACKNOWLEDGEMENTS

The authors are grateful to Morris Animal Foundation for their funding of this research. Thanks to Noel Kennedy (RVC) for VetCompass™ software and programming development. We acknowledge the practices who collaborate in VetCompass™.

REFERENCES

1. DAVID, M. V., DOUGLAS, H. T. & JULIUS, M. L. 2020. Withrow and MacEwen's Small Animal Clinical Oncology - E-Book, St. Louis, Missouri, Saunders.